Literature DB >> 17643225

[Particular features of steroid-induced osteoporosis].

G E Hein1.   

Abstract

Glucocorticoid-induced osteoporosis (GIOP) is characterized by disturbed bone remodelling with consequent reduced bone mass and abnormally low quality of the bone tissue, resulting in an elevated risk of fracture. Glucocorticoids (GC) inhibit processes of bone formation and accelerate bone degradation, all of which must be taken into account especially in the case of long-term treatment with GC. Appropriate diagnostic procedures must be implemented early in the treatment and throughout the course, as must any preventive (improvement of general condition, calcium, vitamin D) and curative treatment required. When indications are carefully observed and the dosage is constantly checked and adjusted as needed, however, GC are not only helpful and beneficial in the treatment of the basic illnesses they are prescribed for, but on balance can even have a positive effect on bone in phases of high inflammatory activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17643225     DOI: 10.1007/s00132-007-1117-0

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  21 in total

Review 1.  Control of osteoblast function and regulation of bone mass.

Authors:  Shun-ichi Harada; Gideon A Rodan
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

2.  Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis.

Authors:  R N de Nijs; J W Jacobs; J W Bijlsma; W F Lems; R F Laan; H H Houben; E J ter Borg; A M Huisman; G A Bruyn; P L van Oijen; A A Westgeest; A Algra; D M Hofman
Journal:  Rheumatology (Oxford)       Date:  2001-12       Impact factor: 7.580

Review 3.  The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

Authors:  L C Hofbauer; S Khosla; C R Dunstan; D L Lacey; W J Boyle; B L Riggs
Journal:  J Bone Miner Res       Date:  2000-01       Impact factor: 6.741

Review 4.  Use of oral corticosteroids and risk of fractures.

Authors:  T P Van Staa; H G Leufkens; L Abenhaim; B Zhang; C Cooper
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

5.  The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression.

Authors:  Shreyasee Amin; Michael P Lavalley; Robert W Simms; David T Felson
Journal:  J Bone Miner Res       Date:  2002-08       Impact factor: 6.741

6.  Fractures in rheumatoid arthritis: an evaluation of associated risk factors.

Authors:  B A Michel; D A Bloch; F Wolfe; J F Fries
Journal:  J Rheumatol       Date:  1993-10       Impact factor: 4.666

Review 7.  Skeletal involvement in patients with diabetes mellitus.

Authors:  Vincenzo Carnevale; Elisabetta Romagnoli; Emilio D'Erasmo
Journal:  Diabetes Metab Res Rev       Date:  2004 May-Jun       Impact factor: 4.876

8.  Low-dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures?

Authors:  A A van Everdingen; D R Siewertsz van Reesema; J W G Jacobs; J W J Bijlsma
Journal:  Clin Exp Rheumatol       Date:  2003 Mar-Apr       Impact factor: 4.473

9.  Predictors of fractures in early rheumatoid arthritis.

Authors:  B A Michel; D A Bloch; J F Fries
Journal:  J Rheumatol       Date:  1991-06       Impact factor: 4.666

10.  Quantitative computed tomography of the lumbar spine, not dual x-ray absorptiometry, is an independent predictor of prevalent vertebral fractures in postmenopausal women with osteopenia receiving long-term glucocorticoid and hormone-replacement therapy.

Authors:  Q Rehman; T Lang; G Modin; N E Lane
Journal:  Arthritis Rheum       Date:  2002-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.